Treatment-resistant depression (TRD) is depression that doesn’t improve after trying at least two different antidepressants, each taken at an adequate dose for six to eight weeks. It’s more common than most people realize, and it doesn’t mean depression is untreatable. It means the standard first-line approaches haven’t worked, and a different strategy is needed.
How TRD Is Defined
The core criterion is straightforward: if you’ve taken two antidepressants from different classes, at proper doses, for at least six to eight weeks each, and your symptoms haven’t meaningfully improved, that meets the threshold for treatment-resistant depression. The “adequate dose and duration” part matters. Stopping a medication after two weeks because it didn’t seem to help, or taking a dose below the therapeutic range, wouldn’t count as a true failed trial.
This definition sounds precise, but in practice there’s a gray area. Some clinicians consider depression treatment-resistant after two failures; others use a broader spectrum, recognizing degrees of resistance based on how many treatments have been tried. What’s consistent is that TRD isn’t a fundamentally different disease from major depressive disorder. It’s the same condition, but one that hasn’t responded to the most common treatments.
How Common It Is
Estimates vary depending on the population studied, but a substantial portion of people with major depressive disorder end up meeting criteria for TRD. Some studies place the figure around 30 to 40 percent of people being treated for depression. A large cross-sectional study found a TRD prevalence of 41.5% among patients being followed for major depressive disorder. That’s not a small subgroup. If you’re in this situation, you’re far from alone.
Why Some Depression Doesn’t Respond
Most standard antidepressants work by increasing the availability of serotonin, norepinephrine, or both. But depression involves more than these two chemical systems. In people with TRD, there’s growing evidence that a different brain signaling system, one driven by glutamate (the brain’s primary excitatory chemical messenger), plays a key role. Patients with mood disorders tend to have significantly higher glutamate levels in their blood, and there appears to be a disrupted relationship between glutamate signaling and the brain’s ability to form and strengthen neural connections. This helps explain why medications targeting serotonin alone may not be enough for everyone.
Several factors increase the likelihood that depression will prove treatment-resistant, and most of them are co-occurring conditions. A large population-wide cohort study published in JAMA Psychiatry found that people with TRD had notably higher rates of anxiety (60% vs. 44% in non-TRD depression), sleep disorders (28% vs. 19%), chronic stress conditions (36% vs. 28%), substance use disorders (15% vs. 11%), and personality disorders (6% vs. 3%). Physical health conditions like cardiovascular disease, diabetes, and thyroid problems showed much smaller differences between the groups, suggesting that psychiatric comorbidities are stronger predictors of treatment resistance than most medical ones.
This doesn’t mean anxiety or insomnia cause treatment resistance. But untreated co-occurring conditions can blunt the effectiveness of antidepressants, and addressing them directly is often part of breaking through.
Medication Augmentation Strategies
When antidepressants alone aren’t working, one of the most common next steps is adding a second medication to boost their effect. Several atypical antipsychotic medications have FDA approval for exactly this purpose. Despite the name “antipsychotic,” these drugs aren’t being used here for psychosis. At low doses, they influence dopamine and serotonin receptors in ways that can amplify an antidepressant’s effect.
The evidence behind these augmentation options varies. In clinical trials, adding aripiprazole to an antidepressant produced remission rates of about 44% compared to 29% with placebo in one study of older adults. The number needed to treat (meaning how many patients need to receive the drug for one additional person to benefit beyond placebo) ranged from 7 to 11 across trials. Brexpiprazole showed meaningful benefits at moderate doses but not at the lowest tested dose. Extended-release quetiapine improved depression severity in two large trials, though results were inconsistent across dosing levels. Cariprazine, the most recently approved option, showed benefit at its lower dose but not the higher one in a trial of 757 patients.
The practical takeaway: augmentation helps a meaningful number of people, but no single add-on medication works for everyone, and finding the right combination often takes trial and adjustment.
Ketamine-Based Treatment
Esketamine, a nasal spray derived from ketamine, represents a fundamentally different approach to treating depression. Unlike traditional antidepressants that take weeks to build up, esketamine works through the glutamate system and can produce noticeable effects within hours to days.
In the largest comparative study to date, involving 676 patients with TRD, esketamine nasal spray combined with a standard antidepressant achieved remission in 27.1% of patients by week 8, compared to 17.6% for those receiving an antidepressant with a different add-on medication. Among those who reached remission, 21.7% in the esketamine group maintained it without relapse through week 32, versus 14.1% in the comparison group. These numbers are modest in absolute terms, but for a population that has already failed multiple treatments, they represent a real option.
Esketamine is administered in a clinical setting because it can cause dissociation, dizziness, and temporary blood pressure changes. You’ll typically stay at the clinic for about two hours after each dose for monitoring. Treatment usually starts twice weekly, then tapers to weekly or every other week.
Brain Stimulation Therapies
Two brain stimulation approaches have established track records in TRD. Electroconvulsive therapy (ECT) involves brief electrical stimulation of the brain under general anesthesia. It carries a reputation that’s far worse than the modern reality: treatments take a few minutes, you’re asleep throughout, and the most common side effect is temporary memory difficulty around the time of treatment. Transcranial magnetic stimulation (TMS) is less invasive, using magnetic pulses delivered through a device placed against your scalp while you sit in a chair, fully awake. A typical course runs daily sessions over four to six weeks.
A large matched study of 586 patients in each group from McLean Hospital found that ECT produced faster improvement in depression severity, greater reductions in suicidal thinking, and better gains in overall functioning compared to TMS during active treatment. However, when researchers compared outcomes at time points approximating a full treatment course for each method, the differences disappeared. Both approaches led to similar endpoints. ECT gets there faster, which can matter when symptoms are severe. TMS offers a less intensive option with fewer side effects for people who can afford a more gradual timeline.
Psilocybin: Where the Evidence Stands
Psilocybin therapy has generated enormous public interest, but the clinical data in treatment-resistant depression specifically is still mixed. The EPISODE trial, a randomized clinical trial of 144 adults with TRD published in JAMA Psychiatry, found no significant difference in response rates at six weeks between the higher psilocybin dose, a low dose, and a placebo-like control. Remission rates at 12 weeks ranged from about 9% to 24% across groups, without a clear dose-dependent pattern. This doesn’t rule psilocybin out, but it’s a reminder that early enthusiasm has run ahead of the evidence for this specific population. Psilocybin is not currently FDA-approved for depression.
What the Treatment Path Looks Like
If you’re facing treatment-resistant depression, the process typically unfolds in stages. First, your provider will confirm that previous medication trials were genuinely adequate in dose and duration. It’s surprisingly common for what looks like treatment resistance to actually reflect underdosed or too-brief trials. From there, options include switching to a different class of antidepressant, augmenting your current antidepressant with one of the approved add-on medications, trying esketamine, or pursuing brain stimulation.
There’s no single correct sequence. The choice depends on how severe your symptoms are, what you’ve already tried, what side effects you’re willing to tolerate, and what’s available near you. TMS and esketamine both require specialized clinics. ECT is generally reserved for the most severe or urgent cases, though it can be appropriate earlier when symptoms include active suicidal thinking.
Throughout this process, psychotherapy remains valuable. Cognitive behavioral therapy and other structured approaches address the patterns of thinking and behavior that medication alone doesn’t touch. For many people with TRD, the combination of a revised medication strategy with ongoing therapy produces the best results. The label “treatment-resistant” describes what hasn’t worked yet. It doesn’t describe what’s possible next.